Authors
Latest:
Dr. Helft Discusses Pancreatic and Carcinoid NETsPaul R. Helft, MD, professor of medicine, Indiana University School of Medicine, Indiana University Health Melvin and Bren Simon Cancer Center, discusses pancreatic and carcinoid neuroendocrine tumors.
Latest:
Dr Sieber on the Importance of Evaluating Comorbidities in Prostate Cancer Prior to ADTPaul Sieber, MD, discusses the importance of evaluating comorbidities in patients with prostate cancer, including assessing risk factors for cardiovascular events in those who are initiating androgen deprivation therapy.
Latest:
Maintaining Bone Health During ADT for Prostate CancerThe use of androgen deprivation therapy in prostate cancer is now a well-established treatment regimen but is associated with an increased risk for bone fracture.
Latest:
Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple MyelomaPaul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.
Latest:
ASH Takeaways and Future Directions for Multiple MyelomaPaul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.
Latest:
Dr. Ruff on the Timing of CRC Treatment With AfliberceptPaul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the decision regarding the timing of treatment with aflibercept for patients with colorectal cancer.
Latest:
Dr. Sabbatini on Frontline Treatment of Newly Diagnosed Ovarian CancerPaul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the frontline treatment of patients with newly diagnosed ovarian cancer.
Latest:
Dr. Ladenson on Diagnosis of Thyroid NodulesDr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules
Latest:
Rapid-Response System Enhances Palliative Care, Lowers CostsA collaborative patient reported outcome-based care approach resulted in better outpatient symptom management and a decrease in end-of-life hospitalizations and costs for late-stage cancer patients.
Latest:
Companion Diagnostics Are Driving Support in the Evolving Regulatory LandscapeOwing to the high clinical failure rates, genetically variable tumor characteristics, and skyrocketing drug development costs, the era of traditional blockbuster oncology agents has come to an end.
Latest:
Dr. Bates on Stimulating the Immune System With Nanoparticles in RCCPaula J. Bates, PhD, discusses the use of nanoparticles to stimulate the immune system in renal cell carcinoma.
Latest:
Dr. Hoff on Delivering Chemotherapy Until Progression Versus Complete Stop in mCRCPaulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses a meta-analysis of randomized trials that examined the effect of chemotherapy delivered until progression versus complete stop on the overall survival of patients with metastatic colorectal cancer (mCRC).
Latest:
Dr. Barata on the Challenges of Treating Advanced Urothelial CarcinomaPedro C. Barata, MD, MSc, discusses challenges associated with treating advanced urothelial carcinoma.
Latest:
Dr. McGregor on the Goals of ADT in Prostate CancerPei-Chun McGregor, MD, cardio-oncologist and director of Ambulatory Cardiology at VA Boston Healthcare System, instructor in medicine, Brigham and Women’s Hospital, discusses the goals of androgen deprivation therapy (ADT) in the treatment of patients with prostate cancer.
Latest:
Novel T-Cell Engineering Strategy Aims to Reduce GVHD in Lymphoma TransplantationsThis pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.
Latest:
Penny Daugherty on Discussing Patients' GeneticsPenny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.
Latest:
Dr. Kennedy on RAS as a TargetPerry Kennedy, MD, postdoctoral research fellow, H. Lee Moffitt Cancer Center and Research Institute, discusses RAS as a target as well as the NCI RAS Initiative.
Latest:
Dr. Johnstone on Immediate Salvage Therapy for Prostate CancerPeter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.
Latest:
USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical PracticeBarbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.
Latest:
Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast CancerPeter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.
Latest:
Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast CancerPeter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.
Latest:
Dr. Black on the Developments in the Field of Immunotherapy for Bladder CancerPeter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.
Latest:
Dr. Borchmann on Next Steps With Tisagenlecleucel in DLBCLPeter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses next steps with tisagenlecleucel (Kymriah) in diffuse large B-cell lymphoma.
Latest:
Dr. Choyke on Recent Developments in Imaging for Prostate CancerPeter L. Choyke, MD, FACR, discusses recent developments in imaging for prostate cancer.
Latest:
Anti-Lung Cancer Compound ASA404 Progresses to Phase IIIA pivotal phase III study is currently underway to evaluate the efficacy and safety of Novartis’ novel anti-cancer compound ASA404 in patients with non–small cell lung cancer (NSCLC).
